Management of older Hodgkin lymphoma patients
Open Access
- 6 December 2019
- journal article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2019 (1) , 233-242
Abstract
Hodgkin lymphoma (HL) in older patients, commonly defined as ≥60 years of age, is a disease for which survival rates have historically been significantly lower compared with younger patients. Older HL patients appear to have different disease biology compared with younger patients, including increased incidence of mixed cellularity histology, Epstein-Barr virus–related, and advanced-stage disease. For prognostication, several studies have documented the significance of comorbidities and functional status in older HL patients, as well as the importance of achieving initial complete remission. Collectively, selection of therapy for older HL patients should be based in part on functional status, including pretreatment assessment of activities of daily living (ADL), comorbidities, and other geriatric measures (eg, cognition, social support). Treatment of fit older HL patients should be given with curative intent, regardless of disease stage. However, attention should be paid to serious treatment-related toxicities, including risk of treatment-related mortality. Although inclusion of anthracycline therapy is important, bleomycin-containing regimens (eg, doxorubicin, bleomycin, vinblastine, dacarbazine) may lead to prohibitive pulmonary toxicity, and intensive therapies (eg, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) are too toxic. Brentuximab vedotin given sequentially before and after doxorubicin, vinblastine, and dacarbazine to fit, untreated advanced-stage older HL patients was recently shown to be tolerable and highly effective. Therapy for patients who are unfit or frail because of comorbidities and/or ADL loss is less clear and should be individualized with consideration of lower-intensity therapy, such as brentuximab vedotin with or without dacarbazine. Altogether, therapy for older HL patients should be tailored based upon a geriatric assessment, and novel targeted agents should continue to be integrated into treatment paradigms.Keywords
This publication has 52 references indexed in Scilit:
- Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD studyBlood, 2012
- Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patientsBlood, 2008
- The Ratio of FOXP3+ Regulatory T Cells to Granzyme B+ Cytotoxic T/NK Cells Predicts Prognosis in Classical Hodgkin Lymphoma and Is Independent of bcl-2 and MAL ExpressionAmerican Journal of Clinical Pathology, 2007
- Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphomaLeukemia & Lymphoma, 2007
- Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study GroupAnnals of Oncology, 2006
- A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patientsAnnals of Oncology, 2006
- Independent prognostic effect of co-morbidity in lymphoma patients: Results of the population-based Eindhoven Cancer RegistryEuropean Journal of Cancer, 2005
- Treatment of Elderly Hodgkin's Lymphoma Patients with a Novel 5-drug Regimen (ODBEP): A Phase II StudyLeukemia & Lymphoma, 2002
- Patients above Sixty Years Lymphoma Treated with a New Strategy of Age with Hodgkin'sActa Oncologica, 2002
- Long-term survival in Hodgkin's disease patientsEuropean Journal of Cancer, 2000